Dyne Therapeutics (NASDAQ:DYN) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Dyne Therapeutics (NASDAQ:DYN) announced its quarterly earnings results on Tuesday. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04, Zacks reports.

Dyne Therapeutics Trading Up 2.4 %

NASDAQ:DYN opened at $12.18 on Thursday. The company has a market cap of $1.24 billion, a P/E ratio of -3.42 and a beta of 1.11. Dyne Therapeutics has a twelve month low of $11.62 and a twelve month high of $47.45. The company’s 50-day moving average price is $16.51 and its 200-day moving average price is $27.03.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on DYN. Piper Sandler dropped their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Chardan Capital reissued a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday, February 28th. Finally, Robert W. Baird initiated coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $46.00 price target for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $48.64.

Insider Activity at Dyne Therapeutics

In other news, SVP Richard William Scalzo sold 1,455 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the sale, the senior vice president now directly owns 127,078 shares in the company, valued at $3,573,433.36. This represents a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the transaction, the insider now owns 201,685 shares in the company, valued at approximately $5,671,382.20. The trade was a 1.14 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,387 shares of company stock valued at $142,789. Corporate insiders own 20.77% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.